Scalper1 News
Big-cap biotech Alexion Pharmaceuticals (ALXN) agreed to pay $8.4 billion in cash and stock for fellow rare-disease specialist Synageva BioPharma (GEVA) Wednesday, which at $230 a share was more than twice Synageva’s closing price. Alexion stock dipped and Synageva soared in early trading. Alexion agreed to pay $115 in cash and 0.6581 Alexion share for every Synageva share, in a bid to diversify from its sole marketed product, Soliris. Alexion is Scalper1 News
Scalper1 News